Marcus Conrad

Title: Innovations of Marcus Conrad in Non-Apoptotic Regulated Cell Death

Introduction

Marcus Conrad is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biomedical research, particularly in the area of non-apoptotic regulated cell death. With a total of four patents to his name, his work focuses on developing therapeutic compounds that address critical health conditions.

Latest Patents

Conrad's latest patents include "Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death." This invention relates to compounds that inhibit non-apoptotic regulated cell death and includes pharmaceutical compositions containing these compounds. The invention is particularly relevant for treating conditions characterized by non-apoptotic regulated cell death or oxidative stress. Another significant patent is "Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death." Similar to the previous patent, this invention focuses on spiropyrazine compounds that serve as inhibitors of non-apoptotic regulated cell death, with applications in various therapeutic contexts.

Career Highlights

Throughout his career, Marcus Conrad has worked with prestigious research institutions, including Helmholtz Zentrum München and Deutsches Forschungszentrum für Gesundheit und Umwelt. His research has been pivotal in advancing our understanding of cell death mechanisms and their implications for various diseases.

Collaborations

Conrad has collaborated with esteemed colleagues such as Joel Schick and Bettina Proneth. These partnerships have enriched his research and contributed to the development of innovative therapeutic solutions.

Conclusion

Marcus Conrad's work in the field of non-apoptotic regulated cell death exemplifies the impact of innovative research on healthcare. His patents and collaborations highlight the importance of scientific inquiry in developing effective treatments for complex health issues.